Advancing science and improving human health by

unlocking measurement of forces and interactions in biology

Jump to:

“Avidity Escape”, a solid tumor evasion mechanism that should be tested in development of CAR T cell therapies

Read groundbreaking Nature paper

Discover LUMICKS

LUMICKS is the leading supplier of dynamic single-molecule and cell avidity analysis instruments. Our instruments allow researchers – for the first time – to build the crucial and as yet unfinished bridge between structure and function at both a molecular and a cellular level. This is achieved by applying and measuring forces around biological interactions, enabling the detailed real-time analysis of underlying biological mechanisms.

Our goal is to advance science and improve human health by providing tools that unlock the measurement of forces and interactions in biology to provide unparalleled insight into the fundamental cause of disease and the potential for drug optimization. These technologies are rapidly evolving as a mainstream approach in academic and pharma research for the study of DNA-binding proteins, molecular motor activity, protein folding, and the interactions between immune and cancer cells.

Do you want to see your biomolecules or cells in action?  Contact us for a demo!

Explore our products & applications

Reveal biomolecular processes
with dynamic single-molecule analysis

Obtain direct proof of the mechanisms of biomolecular processes by making real-time videos of your molecules in action with our dynamic single-molecule microscopes.

Study molecular mechanisms involved in DNA organization, repair, replication, editing, and transcription.

Study how proteins fold correctly and undergo conformational changes to accomplish their biological function.

Study the activity and mechanical properties of cytoskeleton filaments and their motors.

Measure protein droplet assembly, fusion, and droplet or cellular properties in real-time.

Accelerate immunotherapy
with cell avidity analysis

Measure the binding strength between cells and their targets with the z-Movi®Cell Avidity Analyzer to accelerate the development of immunotherapeutic strategies.

CAR T cells

Select optimally-functioning CAR T cells based on their avidity and fine-tune the desired avidities to avoid on-target/off-tumor binding.

TCR T cells

Improve the functional correlation of TCR T cells by replacing affinity measurements with avidity. Reveal TCR modified T cells with optimal avidity that improve T cell responses.

Cell engagers

Test the binding avidity associated with different BsAb and compare the avidity of T cells engaged by these BsAb to find the most desirable response.

CAR-NK / NK cells
Compare the avidity of NK or CAR-NK cells from different donors and correlate the respective outcomes to effector cell functionalities, such as cell killing.

Become a part of the team

Our ultimate dream is to advance science and improve human health. To achieve this together, we are looking for smart and open people with a passion for cutting-edge technology, who are curious to discover new areas and are creative in finding solutions for existing and future challenges.

“We are a flat company that [...] allows you to be thinking creatively and to be your own person at work. This makes me feel that I belong here.”

AidaEMEAI Field Application Scientist Manager

“We are working with things that have never been done before, [but] when you own something, you have the drive to really push to seek completion.”

AbelSoftware Engineer

“We have people from different parts of the world [...] and you get to know so many things, just by working here. People are extremely friendly, approachable and helpful.”

IreneField Application Scientist

Read our latest news

“Avidity Enhancement” As New Strategy for Improving CAR T Therapy for AML
Press releases

Cancer Cell Paper Identifies “Avidity Enhancement” As New Strategy for Improving CAR T Therapy for Acute Myeloid Leukemia

The study details a novel strategy for better cancer treatment with CAR T cells for AML. "Avidity Enhancement", increasing cell-cell binding from both the tumor and CAR T cell side, led to a more effective eradication of tumors in mouse models of AML.
Press releases
LUMICKS Appoints Andre Nel as Chief Financial Officer
Press releases
Nature Paper Identifies “Avidity Escape” as Solid Tumor Evasion Mechanism of CAR T Cell Cancer Therapies
Browse more of our press releases
Blog posts

LUMICKS’ C-Trap® adopted by two labs at UBC

We are delighted to announce the installation of two C-Trap® instruments at the University of British Columbia (UBC), Vancouver, Canada, in the labs of Dr. Derek Dee and Dr. Nada Lallous. Derek Dee, Assistant Professor in the Department of Land and Food Systems, focuses his research on the forces that…
Blog posts
Dynamic single-molecule analysis reveals non-linear stiffening of mitotic chromosomes
Blog posts
C-Trap® studies reveal GroEL-ES protein folding acceleration mechanism
Browse more of our blog posts